Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4252W HIGH $18.23
Volume
520.56 K
Value Traded
971.00 K
Short % Float
2.61%
Days to Cover
2.0
-5.73%Week
-3.21%1 Month
+4.02%3 Month
-31.7%6 Month
-99.99%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
76.60 M
EPS (TTM)
-8.20
P/E Ratio
-
Ent. Value
63.87 M
Total Shares
38.64 M
Float Shares
29.70 M
Insiders
41.59%
Institutions
16.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
STSS Catalyst Timeline
Dated clinical, regulatory and corporate events for Sharps Technology Inc.
Past FDA Catalysts and PDUFA Decisions
How STSS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Sharps Technology Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every STSS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bastion Trading Ltd10% Owner | Buy | 44,000 1,429,417 held | $1.78 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STSS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in STSS for Q2 2026. | ||||
Ownership Trends
STSS Short Interest
Shares sold short, counted twice a month.
2.61%
Short % of Float
of tradable shares sold short
588.4K
Shares Sold Short
-1.2% vs prior count
2.0 Low
Days to Cover
trading days of normal volume to buy every short share back
298.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STSS ranks across every disease it competes in
Competitive Position is a premium feature
See how STSS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTSS News
About Sharps Technology Inc.
Headquarters105 MAXESS ROAD, MELVILLE, NY, 11747
BIOPHARMAWATCH ELITE PLUS
Trade the next STSS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime